Waldenstrom Macroglobulinemia: all 372 studies

Page 3 of 4. Open to participants first (63), then studies with results posted, then the rest; newest registration first within each.

• Loncastuximab Tesirine in WMActive, not recruitingNCT05190705Phase 2
• HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHLWithdrawnNCT05176691Phase 1
• Expanded Access Program for Pirtobrutinib for Participants With B-Cell CancerApproved for marketingNCT05172700
• ACALA-R In Predominantly Demyelinating IgM Mediated NeuropathyActive, not recruitingNCT05065554Phase 2
• Study of Oral LOXO-338 in Patients With Advanced Blood CancersCompletedNCT05024045Phase 1
• NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell CancersActive, not recruitingNCT05020678Phase 1
• PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell MalignanciesStatus unknownNCT05003141Phase 1
• B-cell Chronic Lymphoid Malignancies MarkersStatus unknownNCT04952974
• Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-NimTerminatedNCT04947618
• Immune Responses to COVID-19 Vaccination in Lymphoma PatientsCompletedNCT04858568
• Covid-19 Vaccine Responsiveness in MM and WaldenstromCompletedNCT04830046
• Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)WithdrawnNCT04665115Phase 2
• Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaWithdrawnNCT04635683Phase 1
• Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's MacroglobulinemiaActive, not recruitingNCT04624906Phase 2
• CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaCompletedNCT04578600Phase 1
• Long-term Follow-up Study for Patients Treated With CLBR001 CAR-TCompletedNCT04488354Phase 1
• 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell CancersActive, not recruitingNCT04464200Phase 1
• Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's MacroglobulinemiaCompletedNCT04463953Phase 2
• CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell MalignanciesCompletedNCT04450069Phase 1
• A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom MacroglobulinemiaCompletedNCT04440059Phase 2
• A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic MalignanciesCompletedNCT04279405Phase 1
• A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4CompletedNCT04274738Phase 1
• Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's MacroglobulinemiaActive, not recruitingNCT04263480Phase 2
• APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström MacroglobulinemiaCompletedNCT04260217Phase 1
• Study of Zanubrutinib in Japanese Participants With B-Cell MalignanciesCompletedNCT04172246Phase 1/2
• Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) TreatmentCompletedNCT04116437Phase 2
• A Clinical Trial of BP1002 in Patients With Advanced Lymphoid MalignanciesActive, not recruitingNCT04072458Phase 1
• A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell MalignanciesNo longer availableNCT04052854
• ERK 1/2 Signaling in Ibrutinib Resistant B-cell MalignanciesWithdrawnNCT04043845Phase 1
• The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT04028479
• BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)CompletedNCT04018248Phase 1
• A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)CompletedNCT03833180Phase 1
• Rifaximin in Patients With Monoclonal GammopathyCompletedNCT03820817Phase 1
• A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLCompletedNCT03740529Phase 1/2
• A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1Status unknownNCT03679455Phase 2
• Efficacy of First Line B-RI for Treatment Naive Waldenström's MacroglobulinemiaActive, not recruitingNCT03620903Phase 2
• Pacritinib in Relapsed/Refractory Lymphoproliferative DisordersTerminatedNCT03601819Phase 1
• Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUSCompletedNCT03521596
• TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin LymphomasCompletedNCT03410901Phase 1
• Study of VTD in Waldenstrom's MacroglobulinemiaStatus unknownNCT03335098Phase 2
• A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCompletedNCT03329950Phase 1
• A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2
• Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin LymphomaActive, not recruitingNCT03147885Phase 1/2
• Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid CancersTerminatedNCT03037645Phase 1/2
• Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHLCompletedNCT03019666Phase 1
• Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT03015896Phase 1/2
• Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus CarriersStatus unknownNCT02991638Phase 3
• Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaStatus unknownNCT02981745Phase 1/2
• PCD Versus RCD for the Treatment of Patients With Waldenstrom's MacroglobulinemiaStatus unknownNCT02971982Phase 1/2
• Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's MacroglobulinemiaCompletedNCT02962401Phase 2
• Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromActive, not recruitingNCT02952508Phase 2
• Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02950220Phase 1
• Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATGCompletedNCT02916979Phase 1
• Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström MacroglobulinemiaCompletedNCT02844361Phase 4
• The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström MacroglobulinemiaCompletedNCT02844322Phase 4
• The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WMCompletedNCT02844309Phase 4
• Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
• Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaCompletedNCT02652715Not applicable
• Expression of Ku70/XRCC6 in Waldenström's MacroglobulinemiaCompletedNCT02640287Not applicable
• Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia'sCompletedNCT02371148Phase 2
• Study of Lenalidomide in Relapse/Refractory Waldenstrom MacroglobulinemiaCompletedNCT02302469Phase 1/2
• B-Cell Hematologic Malignancy Vaccination RegistryWithdrawnNCT02298816
• Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02281279Phase 1/2
• CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT02168907Phase 1
• Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionTerminatedNCT02109224Phase 1
• Study of the Glutaminase Inhibitor CB-839 in Hematological TumorsCompletedNCT02071888Phase 1
• Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell LymphomaCompletedNCT02049541Phase 1
• Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell TransplantCompletedNCT01959477Early Phase 1
• Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin LymphomaActive, not recruitingNCT01815749Phase 1
• A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell MalignanciesCompletedNCT01805375Phase 1
• A Long-term Extension Study of PCI-32765 (Ibrutinib)Active, not recruitingNCT01804686Phase 3
• Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's MacroglobulinemiaCompletedNCT01788020Phase 3
• Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin LymphomaWithdrawnNCT01769911Not applicable
• MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaCompletedNCT01748721Phase 1
• Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid MalignanciesTerminatedNCT01744912Phase 1
• Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01658319Phase 1
• Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesWithdrawnNCT01652014Phase 2
• Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT01647971Phase 1/2
• Randomised Trial in Waldenstrom's MacroglobulinaemiaCompletedNCT01592981Phase 2
• Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
• Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell LymphomaCompletedNCT01567709Phase 1
• Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid MalignanciesCompletedNCT01523223Phase 1
• Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's LymphomaActive, not recruitingNCT01479842Phase 1
• Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic MalignanciesTerminatedNCT01416428Phase 1/2
• Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaCompletedNCT01351935Phase 1
• Nonmyeloablative Allogeneic TransplantCompletedNCT01272817Not applicable
• Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersCompletedNCT01254578Phase 1
• Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin LymphomaCompletedNCT01239875Early Phase 1
• MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
• Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
• Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related DisordersActive, not recruitingNCT01177527
• High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
• T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic MalignanciesWithdrawnNCT01163201Phase 1/2
• RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsCompletedNCT01158274Phase 1
• A Study of Belimumab in Treating Symptomatic Waldenstroms MacroglobulinaemiaStatus unknownNCT01142011Phase 2
• AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or LymphomaCompletedNCT01129193Phase 1
• Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom MacroglobulinemiaCompletedNCT01118689Phase 1
• Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaTerminatedNCT01116154Phase 1
• Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's MacroglobulinemiaCompletedNCT01046006Phase 2
• Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin LymphomaTerminatedNCT01045928Phase 1

← Waldenstrom Macroglobulinemia overview